-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga·07/28/2026 13:14:13
Listen to the news
Canaccord Genuity analyst Whitney Ijem initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces Price Target of $35.